355 related articles for article (PubMed ID: 30103548)
1. Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells.
Patel JA; Shen L; Hall SM; Benyahia C; Norel X; McAnulty RJ; Moledina S; Silverstein AM; Whittle BJ; Clapp LH
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103548
[TBL] [Abstract][Full Text] [Related]
2. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.
Clapp LH; Gurung R
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():56-71. PubMed ID: 25917921
[TBL] [Abstract][Full Text] [Related]
3. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196
[TBL] [Abstract][Full Text] [Related]
4. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
[TBL] [Abstract][Full Text] [Related]
5. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
Whittle BJ; Silverstein AM; Mottola DM; Clapp LH
Biochem Pharmacol; 2012 Jul; 84(1):68-75. PubMed ID: 22480736
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension.
Shen L; Patel JA; Norel X; Moledina S; Whittle BJ; von Kessler K; Sista P; Clapp LH
Biochem Pharmacol; 2019 Aug; 166():242-252. PubMed ID: 31158340
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
[TBL] [Abstract][Full Text] [Related]
8. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Benyahia C; Boukais K; Gomez I; Silverstein A; Clapp L; Fabre A; Danel C; Leséche G; Longrois D; Norel X
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():48-55. PubMed ID: 23850788
[TBL] [Abstract][Full Text] [Related]
10. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.
Falcetti E; Hall SM; Phillips PG; Patel J; Morrell NW; Haworth SG; Clapp LH
Am J Respir Crit Care Med; 2010 Nov; 182(9):1161-70. PubMed ID: 20622039
[TBL] [Abstract][Full Text] [Related]
11. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.
Orie NN; Clapp LH
Eur J Pharmacol; 2011 Mar; 654(3):258-65. PubMed ID: 21185823
[TBL] [Abstract][Full Text] [Related]
12. Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.
He Y; Zuo C; Jia D; Bai P; Kong D; Chen D; Liu G; Li J; Wang Y; Chen G; Yan S; Xiao B; Zhang J; Piao L; Li Y; Deng Y; Li B; Roux PP; Andreasson KI; Breyer RM; Su Y; Wang J; Lyu A; Shen Y; Yu Y
Am J Respir Crit Care Med; 2020 May; 201(10):1263-1276. PubMed ID: 31917615
[No Abstract] [Full Text] [Related]
13. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Morrison K; Ernst R; Hess P; Studer R; Clozel M
J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124
[TBL] [Abstract][Full Text] [Related]
14. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
[TBL] [Abstract][Full Text] [Related]
15. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
16. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension.
Lai YJ; Pullamsetti SS; Dony E; Weissmann N; Butrous G; Banat GA; Ghofrani HA; Seeger W; Grimminger F; Schermuly RT
Am J Respir Crit Care Med; 2008 Jul; 178(2):188-96. PubMed ID: 18467507
[TBL] [Abstract][Full Text] [Related]
17. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
18. Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension.
Abu-Hanna J; Anastasakis E; Patel JA; Eddama MMR; Denton CP; Taanman JW; Abraham D; Clapp LH
Vascul Pharmacol; 2023 Aug; 151():107194. PubMed ID: 37442283
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
Akagi S; Nakamura K; Matsubara H; Kusano KF; Kataoka N; Oto T; Miyaji K; Miura A; Ogawa A; Yoshida M; Ueda-Ishibashi H; Yutani C; Ito H
Int J Cardiol; 2013 May; 165(3):499-505. PubMed ID: 21955608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
